Axogen completed its acquisition of BioCircuit Technologies, maker of the first FDA-cleared sutureless nerve repair device, expected to add about $34 million to 2027 revenue.
We only link to sources you can read without a subscription. How we check.
Clayton, Dubilier & Rice and McKesson agreed to acquire Option Care Health for $32.05 per share in a deal valued at about $5.8 billion. CD&R will hold majority ownership, while McKesson invests roughly $1.4 billion for about 49%, with a framework to potentially buy CD&R's stake later. Option Care shares jumped about 34%.
Harbor Health agreed to buy 27 Village Medical clinics in Greater Houston, bringing it to nearly 70 clinics; terms were not disclosed.
The Joint Corp. reacquired regional developer rights across Texas, including Dallas, Austin, San Antonio and Houston.
Japan's Shionogi agreed to acquire Texas-based IntraBio for $2 billion, adding the marketed drug Aqneursa for Niemann-Pick disease type C and Ataxia-Telangiectasia. IntraBio reported sales of $68 million in 2025. The purchase follows Shionogi's acquisitions of Radicava and Tetra Therapeutics as it builds out a rare neurodegenerative disease franchise.